🇺🇸 Terbutaline sulphate in United States
82 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 23 April 2025 – 23 April 2026
- Total reports: 82
Most-reported reactions
- Dyspnoea — 17 reports (20.73%)
- Chest Discomfort — 10 reports (12.2%)
- Anaemia — 8 reports (9.76%)
- Lactic Acidosis — 8 reports (9.76%)
- Asthma — 7 reports (8.54%)
- Thrombocytopenia — 7 reports (8.54%)
- Wheezing — 7 reports (8.54%)
- Influenza Like Illness — 6 reports (7.32%)
- Lethargy — 6 reports (7.32%)
- Neutropenia — 6 reports (7.32%)
Other Respiratory approved in United States
Frequently asked questions
Is Terbutaline sulphate approved in United States?
Terbutaline sulphate does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Terbutaline sulphate in United States?
AstraZeneca is the originator. The local marketing authorisation holder may differ — check the official source linked above.